DEA to Reclassify Marijuana: Official Confirms Looming Marijuana Decision
In a recent interview with aNewDomain, DEA staff coordinator Russ Baer confirmed reports that the DEA is considering reclassifying marijuana off the Schedule 1 list of controlled substances, and indicated that the enforcement of marijuana policy is not a top priority for the federal agency. Although stopping short of offering any specific details about how exactly marijuana might be reclassified, Baer did confirm the genuineness of a recently leaked letter from the DEA to the senate that stated the agency was hoping to reach a decision on whether or not to reclassify marijuana by mid-year. Baer downplayed the mid-year estimate though, stating, “We aren't holding ourselves to any artificial timeframe.”
While an official decision is still yet to be announced, speculation is strong that the DEA will indeed reclassify marijuana from a Schedule 1 drug to a Schedule 2 drug sometime this summer. Recently, an anonymous attorney for the DEA was reported by the Santa Monica Observer as stating that the DEA would soon reclassify marijuana to the schedule 2 list, sending marijuana industries and cannabis communities into watch and wait mode. The DEA's decision to reclassify marijuana to schedule 2 could have a significant impact on both the recreational marijuana and medical marijuana industries, and feelings are mixed as potential effects and consequences are still unclear.
Reclassifying marijuana from a Schedule 1 drug to a Schedule 2 drug makes medical marijuana legal at the federal level. This means that residents of any state could obtain a medical prescription for marijuana and be able to legally use it without fear of criminal charges, neither at the state nor federal level. “We’re not going to go chase after the mom who picks up cannabinol (CBD) in (one) state for her epileptic child and takes it to another state … ,” Baer stated.

